The present invention provides methods of treating, preventing or amelioratingthe symptoms of T cell-mediated immunological diseases, particularly autoimmunediseases, through the use of anti-CD3 antibodies. In particular, the methodsof the invention provide for administration of antibodies that specificallybind the epsilon subunit within the human CD3 complex. Such antibodies modulatethe T cell receptor/alloantigen interaction and, thus, regulate the T cell mediatedcytotoxicity associated with autoimmune disorders. Additionally, the inventionprovides for modification of the anti-CD3 antibodies such that they exhibitreduced or eliminated effector function and T cell activation as compared tonon- modified anti-CD3 antibodies.
